Tag:
Teva
Latest Headlines
Latest Headlines
What's Mylan worth? For big exec bonuses, $73 per share. For Teva, lots more
Mylan may be demanding more than $100 per share from suitor Teva if it wants to talk takeover. But for itself--and its executives--its expectations aren't nearly that high.
One 'cultural difference' between Teva and Mylan? Coury's $22.5M pay wouldn't fly at Teva
Since before Teva even made its now-rejected $40 billion offer to buy Mylan, its target's exec chairman, Robert Coury, has been pretty down on the idea, citing a potential culture clash between the two companies. While Teva CEO Erez Vigodman has said he thinks they'd get along just fine, the rival drugmakers do have a few big differences between them--including their approach to executive compensation.
Small group of branded drugs like Nexium, Copaxone make up huge part of Medicare spend
It's a good thing for Medicare that AstraZeneca's Nexium has gone generic and Teva's Copaxone is headed that way. That is because they are among about 10% of the drugs covered by Medicare which account for about 25% of the cost.
Teva CEO 'takes the high road' to rebut Mylan chairman's attack
Hold it right there, Mylan, Teva said in a Wednesday letter to that company's executive chairman. A couple days after receiving a scathing rejection to its $40 billion buyout bid, the Israeli drugmaker has a few things it wants to set straight.
Drug shortages become issue in Teva and Mylan hook-up
Of the 31 drugs shortages listed in the last couple of months, Mylan was a producer of 9 of them and Teva of 5 and in two cases, they both produced the same drug, the supplies of which were limited in some fashion. And if Teva is able to convince Mylan to join forces, this kind of information will be crucial to a review by antitrust regulators.
Mylan recalls injectable cancer meds, most produced for Pfizer
Mylan is recalling 8 lots of injectable cancer drugs, most of them manufactured for Pfizer, after particulate was discovered in vials.
Teva's recent history gives Mylan chairman plenty of anti-buyout zingers
On Monday, Mylan slapped Teva with a laundry list of reasons it wasn't interested in a tie-up. But for Mylan, the problems with a get-together go beyond the business--and Chairman Robert Coury said as much before the Israeli drugmaker came forth with its $40 billion bid.
Undeterred by Perrigo rejection, Mylan tells Teva to step off
On Friday, Mylan all but rejected Teva's takeover bid with its own sweetened bid for Ireland's Perrigo. But now, it's made the snub official, delivering a resounding "no" to its generics rival.
What price MS therapy? Thanks to price hikes, $50K-plus, even for decades-old meds
The cost of multiple sclerosis drugs has skyrocketed over the past 20 years, and it's not just new drugs driving that increase. Not one MS drug has a list price of less than $50,000 per year in the U.S., and some treatments cost 7 times more now than they did in 1995, a new study found.
Hours after receiving new bid, Perrigo tells Mylan to take a hike
Just a couple hours after Mylan sweetened its original bid for Ireland's Perrigo to $31 billion-plus, Perrigo nixed the new offer. Why? The way the target sees it, it isn't quite so sweet.
